Pharmacokinetics of meloxicam in rabbits after single and repeat oral dosing

Comparative Medicine

Volumn 56, Issue 1, 2006, Pages 63-67

  Turner, Patricia V ^a   Chen, H Cheng ^a,b   Taylor, W Michael ^a  

^a UNIVERSITY OF GUELPH   (Canada)

^b UNIVERSITY PUTRA MALAYSIA   (Malaysia)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; CHLORIDE ION; CREATININE; EMLA; GAMMA GLUTAMYLTRANSFERASE; GLUCOSE; MELOXICAM; POTASSIUM ION; PROTEIN; SODIUM ION; UREA;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG METABOLISM; ENZYME INHIBITION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IC 50; MULTIPLE DRUG DOSE; NONHUMAN; RABBIT; SINGLE DRUG DOSE;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; RABBITS; THIAZINES; THIAZOLES;

EID: 33646487759     PISSN: 15320820     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Baert K, de Backer P. 2002. Disposition of sodium salicylate, flunixin and meloxicam after intravenous administration in broiler chickens. J Vet Pharmacol Therap 25:449-453.
2. Budsberg SC, Cross AR, Quandt JE, Pablo LS, Runk AR. 2002. Evaluation of intravenous administration of meloxicam for perioperative pain management following stifle joint surgery in dogs. Am J Vet Res 63:1557-1563.
3. Busch U, Schmid J, Heinzel G, Schmaus H, Baierl J, Huber C, Roth W. 1998. Pharmacokinetics of meloxicam in animals and the relevance to humans. Drug Metab Disp 26:576-584.
4. Canadian Council on Animal Care. 1993. Guide to the care and use of experimental animals, vol. 1,2nd ed. Ottawa (Ontario):Canada.
5. Czerniak R. 2001. Gender-based differences in pharmacokinetics in laboratory animal models. Int J Toxicol 20:161-163.
6. Engelhardt G, Homma D, Schlegel K, Utzmann R, Schnitzler C. 1995. Anti-inflammatory, analgesic, antipyretic, and related properties of meloxicam, a new non-steroidal anti-inflammatory agent with favourable gastrointestinal tolerance. Inflamm Res 44:423-433.
7. Engelhardt G, Homma D, Schnitzler C. 1995. Meloxicam: a potent inhibitor of adjuvant arthritis in the Lewis Rat. Inflamm Res 44:548-555.
8. Gunaratna C. 2001. Drug metabolism and pharmacokinetics in drug discovery: a primer for bioanalytical chemists, part ii. Curr Separations 19(3):87-92.
9. Hawkey CJ. 1997. The gastroenterologist's caseload: contribution of the rheumatologist. Sem Arth Rheum 26:11-15.
10. Jones CJ, Streppa HK, Harmon BG, Budsberg SC. 2002. In vivo effects of meloxicam and aspirin on blood, gastric mucosal, and synovial fluid prostanoid synthesis in dogs. Am J Vet Res 63:1527-1531.
11. Kam PCA, See AU.2000. Cyclooxygenaseisoenzymes: physiological and pharmacological role. Anaesthesia 55:442-449.
12. Kay-Mugford P, Benn SJ, LaMarre J, Conlon P.2000. In vitro effects of nonsteroidal anti-inflammatory drugs on cyclooxygenase activity in dogs. Am J Vet Res 61:802-810.
13. Laird JMA, Herrero JF, Garcia de la Rubia P, Cervero F. 1997. Analgesic activity of the novel COX-2 preferring NSAID meloxicam in mono-arthritic rats: central and peripheral components. Inflamm Res 46:203-210.
14. Montoya L, Ambros L, Kreil V, Bonafine R, Albarellos G, Hallu R, Soraci A. 2004. A pharmacokinetic comparison of meloxicam and ketoprofen following oral administration to healthy dogs. Vet Res Comm 28:415-428.
15. Pairet M, van Ryn J, Schierok H, Mauz A, Trummlitz G, Engelhardt G. 1998. Differential inhibition of cyclooxygenases-1 and -2 by meloxicam and its 4′-isomer. Inflamm Res 47:270-276.
16. Roughan JV, Flecknell PA. 2003. Evaluation of a short duration behaviour-based post-operative pain scoring system in rats. Eur J Pain 7:397-406.
17. Salhab AS, Amro BI, Shomaf MS. 2003. Further investigation on meloxicam contraceptivity in female rabbits: luteinizing unruptured follicles, a microscopic evidence. Contraception 67:485-489.
18. Schmid J, Busch U, Heinzel G, Bozler G, Kaschke S, Kummer M. 1995. Meloxicam pharmacokinetics and metabolic pattern after intravenous infusion and oral administration to healthy subjects. Drug Metab Disp 23:1206-1213.
19. Schmid J, Busch U, Trummlitz G, Prox A, Kaschke S, Wachsmuth H. 1995. Meloxicam: metabolic profile and biotransformation products in the rat. Xenobiotica 25:1219-1236.
20. Solomon DH, Gurwitz JH. 1997. Toxicity of nonsteroidal antiinflammatory drugs in the elderly: is advanced age a risk factor? Am J Med 102:208-215.
21. Taylor WM. Unpublished data.
22. Toutain P-L, N Raymond, V Laroute, P Garcia, M-A Popot, Y Bonnaire, A Hirsch, R Narbe. 2004. Pharmacokinetics of meloxicam in plasma and urine of horses. Am J Vet Res 65:1542-1547.
23. Turck D, Roth W, Busch U. 1996. A review of the clinical pharmacokinetics of meloxicam. Br J Rheumatol 35(Suppl 1):13-16.
24. Turner PV, Kerr C, Healey A, Taylor WM. 2006. Meloxicam potentiates butorphanol reduction of the minimum alveolar concentration of isoflurane in rabbits. Am J Vet Res. Forthcoming.
25. Villegas I, Alarcon de la Lastra C, Martin MJ, Motilva V, La Casa Garcia C. 2002. Gastric damage induced by subchronic administration of preferential cyclooxygenase-1 and cyclooxygenase-2 inhibitors in rats. Pharmacology 66:68-75.